Anna Mae Diehl
Professor of Medicine, Duke University USA
Global Engage is pleased to announce the Global NASH Congress 2018, which will be taking place 26-27 February 2018 in London.
Featuring small group roundtable discussions and ample networking time, the event provides an excellent opportunity to meet and collaborate with senior representatives from industry, hospitals and universities. During the two-day conference, there will be 40 expert-led presentations, interactive panel and roundtable discussions exploring key issues, and a dynamic exhibition room filled with technology providers showcasing relevant solutions.
A selection of 2018 Speakers include:
CEO, Jecure Therapeutics, USA Magda Gunn, Scientific Project Manager Responsible Strategic Area Diabetes & Metabolic Disorders, Innovative Medicines Initiative, Belgium
Professor of Experimental Hepatology & Consultant Hepatologist, Institute of Celluar Medicine, Newcastle University, UK
Lead Medical Officer, DGIEP Liver Team IV, Center for Drug Evaluation and Research, Food and Drug Administration, USA
President of the European Society of Pathology, Director of the Department of Pathology, Physiology and Imaging, Hôpital Beaujon, Université Paris Diderot, France
Attracting experts working in all areas of nonalcoholic steatohepatitis, the conference will examine the latest research and development in pathogenesis, diagnosis and treatment of the disease.
An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.
There are, however, promising developments in research that will hopefully bolster drug development and other methods of treatment. Examples of such developments include improved in vivo liver models, non-invasive diagnostic biomarkers and a better understanding of the disease’s mechanisms. This year’s congress will focus on these exciting advancements, as well as on the challenges of preclinical and clinical research in NASH. There will also be a session on business development/regulation and a showcase of the most promising therapeutics in development.